You are here

  • Home
  • Archive
  • Volume 31, Issue Suppl 4
  • EPV066/#382 Preliminary results of niraparib and brivanib dual therapy evaluation in recurrent, metastatic and persistent cervical cancer (CQGOG0101: an open-label, single arm, phase II clinical trial

Article info

Article menu

Download PDFPDF

E-Posters
E-Poster Viewing
EPV066/#382 Preliminary results of niraparib and brivanib dual therapy evaluation in recurrent, metastatic and persistent cervical cancer (CQGOG0101: an open-label, single arm, phase II clinical trial
Free

Authors

Citation

Zou D, Wang H, Shu J, et al
EPV066/#382 Preliminary results of niraparib and brivanib dual therapy evaluation in recurrent, metastatic and persistent cervical cancer (CQGOG0101: an open-label, single arm, phase II clinical trial
International Journal of Gynecologic Cancer 2021;31:A55.

Publication history

  • First published November 1, 2021.
Online issue publication 
January 08, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© IGCS and ESGO 2021. No commercial re-use. See rights and permissions. Published by BMJ.